Emerging DNA topoisomerase inhibitors as anticancer drugs

Bibliography

• LIU LF: DNA topoisomerase poisons as antitumor drugs. Ann. Rev Biochem. (1989) 58:351–375.
   PubMed Web of Science ®Google Scholar
• DENNY WA, BAGULEY BC: Dual topoisomerase I/II inhibitors. Curr. Top. Med. Chem. (2003) 3:339–353.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM, CREAVEN PJ, HANSEN HH, COHEN MH, SELAWRY OS: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. (1972) 56(4):515–521.
   PubMedGoogle Scholar
• GOTTLIEB JA, GUARINO AM, CALL JB, OLIVERIO VT, BLOCK JB: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep. (1970) 54(6):461–470.
   PubMedGoogle Scholar
• JEWS, KIM MG, KIM HJ et al.: Synthesis and in vitro cytotoxicity of C(20) (RS)-camptothecin analogs modified at both B (or A) and E ring. Bioorg. Med. Chem. Lett. (1998) 8(14):1797–1800.
   PubMed Web of Science ®Google Scholar
• AHN SK, CHOI NS, JEONG BS et al: Practical synthesis of (S)-7-(2-isopropylamino)ethylcamptothecin hydrochloride, potent topoisomerase I inhibitor. J. Het. Chem. (2000) 37(5):1141–1144.
   Web of Science ®Google Scholar
• LEE JH, LEE JM, KIM JK et al.: Antitumor activity of 7- [2-(N isopropylamino)ethyl]-(205)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch. Pharm. Res. (1998) 21(5):581–590.
   PubMed Web of Science ®Google Scholar
• •Enzyme inhibition and in vitro cytotoxicity data.
   Google Scholar
• LEE JH, LEE JM, LIM KH et al.: Preclinical and Phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann. NY Acad. Sri. (2000) 922:324–325.
   PubMed Web of Science ®Google Scholar
• LEE HS, PARK HJ, LEE JH et al: Preclinical evaluation of oral CKD-602, a novel camptothecin derivative. Proc. Am. Assoc. Cancer Res. (2003) 44:404 (Abstract 1781).
   Google Scholar
• HA KW, OH HY, HEO OS et al.: Genotoxicity studies of an anticancer agent of camptothecin series, CKD-602. Env Mutagens Carcinogens (1998) 18(2):129–134.
   Google Scholar
• KIM HK, BANG YJ, HOE DS, SHIN SG, KIM NK: Phase I trial of CKD-602, a novel camptothecin derivative, in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 393).
   Web of Science ®Google Scholar
• CHO JY, SEO HB, YU KS et al: Simple and sensitive determination of the new antitumor drug CKD-602 in human plasma by liquid chromatography. j Chromat. B-Anal. TechnoL Biomed. Life Li. (2003) 784(1):25–31.
   PubMed Web of Science ®Google Scholar
• SONG Y, SEO SS, BANG YJ et al: Phase II evaluation of CDK-602, a camptothecin analog, administered on a 5-day schedule in patients with recurrent or refractory ovarian cancer. Proc. Am. Soc. Oncol (2003) 22:467 (Abstract 1877).
   Google Scholar
• BOM D, CURRAN DP, CHAVAN AJ et al.: Novel A,B,E-ring modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities. J. Med. Chem. (1999) 42(16): 3018–3022.
   PubMed Web of Science ®Google Scholar
• KUMAZAWA E, TOHGO A: Antitumor activity of DX-8951f: a new camptothecin derivative. Expert Opin. Investig. Drugs (1998) 7(4):625–632.
   PubMedGoogle Scholar
• KUMAZAWA E, JIMBO T, OCHI Y, TOHGO A: Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice. Cancer Chemother. Pharmacol (1998) 42(3):210–220.
   PubMed Web of Science ®Google Scholar
• •Evidence of in vivo activity in Pgp-overexpressing cell lines.
   Google Scholar
• JOTO N, ISHII M, MINAMI M, KUGA H, MITSUI I, TOHGO A: DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant. Int. Cancer (1997) 72(4):680–686.
   PubMed Web of Science ®Google Scholar
• NOMOTO T, NISHIO K, ISHIDA T, MORI M, SAIJO N: Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f. fpn. Cancer Res. (1998) 89(11):1179–1186.
   PubMed Web of Science ®Google Scholar
• MINAMI H, SASAKI Y, SHIGEOKA Y et al: Phase I study and pharmacology of DX-8951f, a new camptothecin derivative, administered over 30 minutes every 3 weeks. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, Washington DC, USA (1999) (Abstract 326).
   Google Scholar
• ROWINSKY E, JOHNSON T, GEYER C et al.: DX-8951f, a hexacyclic camptothecin analog on a daily x 5 schedule: a Phase I and pharmacokinetic study in patients with advanced solid malignancies. J. Clin. Oncol. (2000) 18(17):3151–3163.
   PubMed Web of Science ®Google Scholar
• •Full Phase I clinical trial report.
   Google Scholar
• ROYCE M, LASSERE Y, HOFF Pet al: DX-8951f: Phase I and pharmacokinetic study of a novel camptothecin analog adm-nistered by 24-hr continuous infusion to patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (1999) 18 (Abstract 682).
   Web of Science ®Google Scholar
• GARRISON M, HAMMOND LA, GEYER C et al.: A Phase land pharmacokinetic study of the camptothecin (CPT) analog DX-8951F (exatecan mesylate): escalating infusion duration and dose. Proc. Am. Soc. Clin. Oncol (2000) 19 (Abstract 765).
   PubMed Web of Science ®Google Scholar
• PATT YZ, ROWINSKY E, O'REILLY E et al.: Phase II trial of DX-8951f (Exatecan Mesylate) In hepatocellular carcinoma (HCC); a final analysis. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 555).
   Web of Science ®Google Scholar
• ESTEVA FJ, RIVERA E, CRISTOFANILLI Met al: A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol (2003) 22:17 (Abstract 67).
   Web of Science ®Google Scholar
• ABOU-ALFA GK, O'REILLY EM, ROWINSKY EK et al.: Final results of a Phase II study of DX-8951f (DX, Exatecan Mesylate) in biliary tree cancers. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 561).
   PubMed Web of Science ®Google Scholar
• KUDELKA A, VERCHRAEGEN CF, VINCENT Met al: Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, Taxane, and Topotecan. Proc. Am. Soc. Clin. Oncol (2000) 19 (Abstract 1550).
   PubMed Web of Science ®Google Scholar
• TALBOT DC, WHITES, JONES P et al: Phase II study of exatecan mesylate (DX-8951f) in advanced NSCLC. Proc. Am. Soc. Clin. Oncol (2000) 19 (Abstract 2166).
   PubMed Web of Science ®Google Scholar
• ROYCE M, SALTZ L, ROWINSKY EK et al.: A Phase II study of intravenous exatecan mesylate (Dx-8951f,Dx) administered daily for five days every three weeks to patients with advanced or metastatic adenocarcinoma of the colon or rectum. Proc. Am. Soc. Clin. Oncol (2000) 19 (Abstract 1129).
   Web of Science ®Google Scholar
• D'ADAMO D, HAMMOND L, DONEHOWER R et al: Final results of a Phase II study of DX-8951f (Exatecan Mesylate, DX) in advanced pancreatic cancer. Proc. Am. Soc. Clin. Oncol (2001) 20 (Abstract 532).
   Web of Science ®Google Scholar
• DALLAVALLE S, FERRARI A, BIASOTTI B, MERLINI L, ZUNINO F: Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity. Med. Chem. (2001) 44(20):3264–3274.
   Web of Science ®Google Scholar
• •Extensive SAR studies showing correlation of enzyme inhibition and in vitro cytotoxicity with lipophilicity.
   Google Scholar
• DALLAVALLE S, FERRARI A, MERLINI L et al.: Novel cytotoxic 7-iminomethyl and 7-aminomethyl derivatives of camptothecin. Bioorg. Med. Chem. Lett. (2001) 11(3):291–294.
   PubMed Web of Science ®Google Scholar
• DI FRANCESCO A, MECO D, PISANO C et al.: Antitumour activity of the novel 7-substituted camptothecin ST1481 (Gimatecan) against the human neuroblastoma SN-K-DZ. Proc. Am. Assoc. Cancer Res. (2003) 44:811 (Abstract 3551).
   Google Scholar
• ZANNA C, CALABRESI P, CORSI Met al: Potent and less schedule-dependent antitumor activity of the oral camptothecin derivative ST 1481. Proc. Am. Soc. Clin. Oncol (2001) 20 (Abstract 406).
   PubMed Web of Science ®Google Scholar
• ALDERSON L, SUPKO J, MAESTRI)(et al: Phase I/II trial of gimatecan in patients with recurrent malignant glioma. Proc. Am. Soc. Clin. Oncol (2003) 22:104 (Abstract 416).
   PubMed Web of Science ®Google Scholar
• ZHU AX, READY NE, CLARK JW et al: Phase I trial of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2003) 22:139 (Abstract 557).
   Web of Science ®Google Scholar
• SESSA C, HESS D, BASELGA Jet al: Concerted escalation of dose and dosing-duration in a Phase I study of the oral camptothecin Gimatecan (ST 1481) in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 386).
   Google Scholar
• ZUCCHETTI M, PACE S, FRAPOLLI Ret al: Clinical pharmacokinetic profile of Gimatecan (ST 1481), a new oral campthotecin derivative. Proc. Am. Soc. Onco. (2002) 21 (Abstract 476).
   Google Scholar
• VAN HATTUM AH, PINEDO HM, SCHLUPER HMM, HAUSHEER FH, BOVEN E: New highly lipophilic captothecin BNP1350 is an effective drug in experimental human cancer. Int. Cancer (2000) 88(2)260–266.
   PubMed Web of Science ®Google Scholar
• VAN HATTUM AH, SCHLUPER HM, HAUSHEER FH, PINEDO HM, BOVEN E: Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance. Int. J. Cancer (2002) 100(1):22–29.
   PubMed Web of Science ®Google Scholar
• KEIR ST, HAUSHEER F, LAWLESS AA,BIGNER DD, FRIEDMAN HS: Therapeutic activity of 74(2-trimethylsilyflethyl)]-20 (5)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. Cancer Chemother. Pharmacol (2001) 48(1):83–87.
   PubMed Web of Science ®Google Scholar
• •Demonstration of in vivo activity in CNS tumours.
   Google Scholar
• YIN MING B, HAPKE G, WU J, AZRAK R, FRANK C, WRZOSEK C, RUSTUM YM: Chkl signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350. Biochem. Biophys. Res. Comm. (2002) 295(2):435–444.
   PubMed Web of Science ®Google Scholar
• SCHILSKY RL, HAUSHEER FH, BERTUCCI D, BERGHORN EJ, KINDLER HL, RATAIN MJ: Phase I trial of karenitecin KT) administered intravenously daily for five consecutive days in patients with advanced solid tumors using accelerated dose titration. Proc. Am. Soc. Clin. Oncol (2000) 19 (Abstract 758).
   Web of Science ®Google Scholar
• THOMPSON P, BERG S, GURURANGAN Set al: A Phase I study of karenitecin in children. Proc. Am. Assoc. Cancer Res. (2002) 43:553 (Abstract 2748).
   Google Scholar
• HERNDON JE, MILLER AA, ZHANG C, GREEN MR: Phase II trial of karenitecin in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004. Proc. Am. Soc. Clin. Oncol (2003) 22:673 (Abstract 2706).
   Google Scholar
• DAUD A, BALAR B, VALKOV Net al: Phase II trial of karenitecin, a novel topoisomerase I inhibitor in metastatic melanoma: clinical and translational study. Proc. Am. Soc. Clin. Oncol (2003) 22:714 (Abstract 2871).
   Google Scholar
• LAVERGNE O, DEMARQUAY D, BAILLY C et al: Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J. Med. Chem. (2000) 43(11):2285–2289.
   PubMed Web of Science ®Google Scholar
• •Extensive SAR studies with homocamptothecin analogues.
   Google Scholar
• LAVERGNE O, LESUEUR GL, PLA RF, BIGG DCH: BN-80245: an E-ring modified camptothecin with potent antiproliferative and topoisomerase I inhibitory activities. Bioorg. Med. Chem. Lett. (1997) 7(17):2235–2238.
   Web of Science ®Google Scholar
• LESUEUR GL, DEMARQUAY D, KISS R, KASPRYZK PG, LAVERGNE 0: Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res. (1999) 59(12):2939–2943.
   PubMed Web of Science ®Google Scholar
• •Detailed studies with diflomtecan.
   Google Scholar
• LAVERGNE O, GINOT L, RODAS F et al.: Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues. J. Med. Chem. (1998) 41(27):5410–5419.
   PubMed Web of Science ®Google Scholar
• GABARDA AE, DU W, ISARNO T et al:Asymmetric total synthesis of (20R)-homocamptothecin, substituted homocamptothecins and homosilatecans. Tetrahedron (2002) 58(32):6329–6341.
   Web of Science ®Google Scholar
• LAVERGNE O, DEMARQUAY D, KASPRZYK PG, BIGG DC: Homocamptothecins: E-ring modified CPT analogues. Ann. NY Acad. ScL (2000) 922:100–111.
   PubMed Web of Science ®Google Scholar
• DEMARQUAY D, HUCHET M, COULOMB Het al: The homocamptothecin BN 80915 is a highly potent orally active topoisomerase I poison. Anticancer Drugs (2001) 12(1):9–19.
   PubMed Web of Science ®Google Scholar
• BAILLY C, LANSIAUX A, DASSONNEVILLE Let al: Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry (1999) 38(47):15556–15563.
   Google Scholar
• PHILIPPART P, HARPER L, CHABOTEAUX Cet al: Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Chi'. Cancer Res. (2000) 6(4):1557–1562.
   PubMed Web of Science ®Google Scholar
• •Comparison with other topo I inhibitors In early passage human tumour lines.
   Google Scholar
• BATES S, PEREZ WM, KOHLHAGEN G, POMMIER YG: BRCP/MXR/ABCG2-mediated resistance to homocamptothecins. Proc. Am. Assoc. Cancer Res. (2003) 44:137 (Abstract 595).
   Google Scholar
• SOLA J, GAY-FEUTRY C, MASSIERE F, PERAIRE C, OBACH R, PRINCIPE P: In vitro metabolism of diflomotecan in humans. Evaluation of the CYP inhibition potential. Drug Met. Rev (2003) 35(Suppl. 1).
   Google Scholar
• BONNETERRE J, COTTUP, ADENIS A, BONETERRE ME et al.: First results of Phase I trial of BN-80915 administered intravenousley in patients with advanced malignant tumors. NCI-EORTC Symposium New Drugs for Cancer Therapy (2000) 11 (Abstract 234).
   Google Scholar
• SOEPENBERG O, SCOTT L, VERWIEJ J, DAMJI R et al: Phase I and pharmacologic study of diflomotecan (BN80915) administered intravenously daily for 5 consecutive days every 3 weeks in patients with solid tumors. 14th EORTC-NCI-AACR Symposium of Molecular Targets and Cancer Therapeutics, Frankfurt, Germany (2002) (Abstract 139).
   Google Scholar
• SALAZAR R, GELDERBLOM AJ, TWELVES CJ, DEJONGE M et al.: A Phase I bioavailability and dose finding study of BN80915 administered orally to patients with advanced malignant tumors. Proc. Am. Soc. Clin. Oncol (2001) 20 (Abstract 418).
   PubMed Web of Science ®Google Scholar
• OHKUBO M, NISHIMURA T, HONMA T et al.: Synthesis and biological activities of NB-506 analogues: effects of the positions of two hydroxyl groups at the indole rings. Bioorg. Med. Chem. Lett. (1999) 9:3307–3312.
   PubMed Web of Science ®Google Scholar
• AKAO A, HIRAGA S, IIDA Tet al: Practical synthesis of a potent indolocarbazole-based, DNA topoisomerase inhibitor. Tetrahedron (2001) 57(43):8917–8923.
   Web of Science ®Google Scholar
• YOSHINARI T, OHKUBO M, FUKASAWA K, EGASHIRA SI, HARA Y: Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. (1999) 59(17):4271–4275.
   PubMed Web of Science ®Google Scholar
• KOMATANI H, KOTANI H, HARA Y et al.: Identification of breast cancer resistant protein/mitoxantrone resistance/ placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res. (2001) 61(7):2827–2832.
   PubMed Web of Science ®Google Scholar
• ••Nice study of efflux mechanisms foredotecarin.
   Google Scholar
• GOOSSENS JF, KLUZA J, VEZIN H et al.: Plasma stability of two glycosyl indolocarbazole antitumor agents. Biochem. Pharmacol (2003) 65(1):25–34.
   PubMed Web of Science ®Google Scholar
• TAKENAGA N, ISHII M, KAMEI T, YASUMORI T: Structure-activity relationship in 0-glucuronidation of indolocarbazole analogs. Drug Met. Disp. (2002) 30(5): 494–497.
   PubMed Web of Science ®Google Scholar
• ARAKAWA H, MORITA M, KODERA T et al: In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice fpn. J. Cancer Res. (1999) 90(10):1163–1170.
   Google Scholar
• PECK RA: Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc. Am. Soc. Clin. Oncol (2000) 19 (Abstract 767).
   Web of Science ®Google Scholar
• YAMADA Y, YAMAMOTO N, SHIMOYAMA Tet al: Phase I trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 385).
   Web of Science ®Google Scholar
• PEREZ RP, HURWITZ H, NAHUM Ket al: Phase II trials of J-107088, a non-camptothecin topoisomerase I inhibitor, in irinotecan naive/refractory metastatic colorectal cancer. Proc. Am. Soc. Chi'. Oncol (2002) 21 (Abstract 632).
   Google Scholar
• NAHUM K, SHIBA D, PADAVANIJA Pet al: Phase II efficacy and tolerability study of edotecarin (J-107088) in patients with irinotecan-nalve metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol (2003) 22:274 (Abstract 1099).
   Google Scholar
• QUINTIERI L, ROSATO A, NAPOLI E et al: In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Cancer Res. (2000) 60(12):3232–3238.
   PubMed Web of Science ®Google Scholar
• •Studies of the liver metabolism of nemorubicin.
   Google Scholar
• BEULZ-RICHE D, ROBERT J, MENARD C, RATANASAVANH D: Metabolism of methoxymorpholino-doxorubicin in rat, dog and monkey liver microsomes: comparison with human microsomes. Fund. Clin. Pharmacol (2001) 15(6):373–378
   PubMed Web of Science ®Google Scholar
• GRANDI M, BALLINARI D, CAPOLONGO Let al: A new anthracycline and multidrug resistance. Haematologica (1991) 76\(Suppl. 3):181–183.
   PubMedGoogle Scholar
• RIPAMONTI M, PEZZONI G, PESENTI E et al: In vivo anti-tumour activity of FCE 23762, a memoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells. BE J. Cancer (1992) 65(5):703–707.
   Web of Science ®Google Scholar
• GRANDI M, PEZZONI G,BALLINARI D et al.: Novel anthracycline analogs. Cancer Treat. Rev (1990) 17(2-3):133–138.
   PubMed Web of Science ®Google Scholar
• BREDA M, BENEDETTI MS, BATTAGLIA Ret al: Species-differences in disposition and reductive metabolism of methoxymorpholinodoxorubicin (PNU 152243), a new potential anticancer agent. Pharmacol Res. (2000) 41(2):239–248.
   PubMed Web of Science ®Google Scholar
• VASEY PA, BISSETT D, STROLIN-BENEDETTI M et al: Phase I clinical and pharmacokinetic study of 3'-deamino 3' (2 methoxy-4-morpholiny0doxorubicin (FCE 23762). Cancer Res. (1995) 55(10)2090–2096.
   PubMed Web of Science ®Google Scholar
• FOKKEMA E, VERWEIJ J, VAN OOSTEROM AT: A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumors: a Phase I and pharmacokinetic study. Br. J. Cancer (2000) 82(4):767–771.
   PubMed Web of Science ®Google Scholar
• •Full Phase I clinical trial report on nemorubicin.
   Google Scholar
• GRAUL A, LEESON PA, CASTANER J: Nemorubicin: antineoplastic anthracycline; Drugs Future (1997) 22(12):1319–1324.
   Google Scholar
• SUN Y, LI H, UN Zet al: Phase land pharmacokinetic study of nemorubicin hydrochloride (methoxymorpholino doxorubicin; PNU-152243) administered with iodinated oil via hepatic artery (IHA) to patients (pt) with unresectable hepatocellular carcinoma (HCC). Proc. Am. Soc. Clin. Oncol. (2003) 22:361 (Abstract 1448).
   Web of Science ®Google Scholar
• UDEA T, FUKUSHIMA T: Recent developments with novel anthracyclines for the treatment of haematological malignancies. Expert Opin. Investig. Drugs (1996) 5(12):1639–1646.
   Google Scholar
• YAMAOKA T, HANADA M, ICHII S, MORISADA S, NOGUCHI T, YANAGI Y: Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. fpn. J. Cancer Res. (1998) 89(10):1067–1073.
   PubMedGoogle Scholar
• •Metabolism and cytotoxicity studies on amrubicin.
   Google Scholar
• OHMORI H, TSUSHIMA T, KOBASHI K: Experimental studies on intravesical instillation of SM-5887, a novel anthracycline derivative for treatment of bladder carcinoma. Gan To Kagaku Ryoho (1996) 23(5):601–606.
   PubMedGoogle Scholar
• HANADA M, NOGUCHI T, MURAYAMA T: Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline. Nippon Yakurigaku Zasshi (2003) 122(2):141–150.
   PubMedGoogle Scholar
• HANADA M, MIZUNO S, FUKUSHIMA A, SAITO Y, NOGUCHI T, YAMAOKA T: A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. fpn..1. Cancer Res. (1998) 89(11):1229–1238.
   Google Scholar
• OHE Y, NAKAGAWA K, FUJI WARA Y et al.: In vitro evaluation of the new anticancer agents KT6149, MX-2, 5M5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Cancer Res. (1989) 49(15):4098–4102.
   PubMed Web of Science ®Google Scholar
• MORISADA S, YANAGI Y, NOGUCHI T, KASHIWAZAKI Y, FUKUI M: Antitumor activities of a novel 9-aminoanthracycline (SM-5997) against mouse experimental tumors and human tumor xenografts. fpn..1. Cancer Res. (1989) 80(1):69–76.
   Google Scholar
• YAMAUCHI S, KUDOH S, KIMURA T, HIRATA K, YOSHIKAWA J: Additive effects of amrubicin with cisplatin on human lung cancer cell lines. Osaka City Med. J. (2002) 48(1):69–76.
   PubMedGoogle Scholar
• NOGUCHI T, ICHII S, MORISADA S, YAMAOKA T, YANAGI Y: h7 vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. lap. J. Cancer Res. (1998) 89(10):1055–1060.
   PubMedGoogle Scholar
• ••Nice correlation between rates ofmetabolism of amrubicin to the 13-alcohol and activity in human xenografts.
   Google Scholar
• TSUJIMOTO S, SATOH E, SUGIMOTO SI et al: General pharmacological studies of a novel anthracycline derivative, (7S, 9S)-9-acetyl-9-amino-7-[(2-deoxy-beta-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-5, 12-naphthacenedione hydrochloride (SM-5997), with antitumor activity. Pharmacomemics (1996) 52(5):351–370.
   Google Scholar
• INOUE K, OGAWA M, HORIKOSHI Net al: Phase I study of SM-5887, a new anthracycline derivative. Gan To Kagaku Ryoho (1988) 15(5):1771–1776.
   Google Scholar
• TSUSHIMA T, OHMORI H: A Phase II study of amrubicin (SM-5997), a novel 9-aminoanthracycline, in patients with superficial bladder cancer: a randomized study of intravesical chemotherapy comparing 6 consecutive day and thre consecutive day-4 day interval treatment schedules. Can. J. Infect. Dis. (1995) 6(Suppl. C).
   Google Scholar
• YANA T, NEGORO S, TAKADA Y, YOKOTA S, FUKUOKA M: Phase II study of amrubicin (SM-5997), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): a West Japan Lung Cancer Group trial. Proc. Am. Soc. OM Oncol (1998) 17 (Abstract 1734).
   Google Scholar
• TEMPERINI C, MESS ORI L, ORIOLI P,DI BUGNO C, ANIMATI F, UGHETTO G: The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes. Nucleic Acids Res. (2003) 31(5):1464–1469.
   PubMed Web of Science ®Google Scholar
• BIGIONI M, SALVATORE C, BULLO A et al.: A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogue. Biochem. Pharmacol. (2001) 62(1):63–70.
   PubMed Web of Science ®Google Scholar
• •Study analysing the relationship between rates of uptake and cardiotoxicity for MEN-10755 and doxorubicin.
   Google Scholar
• ARCAMONE F, ANIMATI F, BERETTONI M et al.: Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. Natl. Cancer Inst. (1997) 89(16):1217–1223.
   PubMed Web of Science ®Google Scholar
• SACCO G, GIAMPIETRO R, SALVATORELLI E et al.: Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.Pharmacol (2003)139(3):641–651. ••In vivo studies correlating thecardiotoxicity of MEN-10775 and other anthracyclines with myocardial levels of the alcohol metabolites.
   Web of Science ®Google Scholar
• MINTTI G, LICATA S, SAPONIERO A et al.: Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analog with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. Chem. Res. Tox. (2000) 13(12):1336–1341.
   PubMed Web of Science ®Google Scholar
• BOS AM, DEVRIES EG, DOMBERNOVSKY Pet al: Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two Phase I studies in adults with advanced solid tumours. Cancer Chemother. Pharmacol (2001) 48(5):361–369.
   PubMed Web of Science ®Google Scholar
• PRATESI G, DECESARE M, CASERINI C et al.: Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts. Clin. Cancer Res. (1998) 4(11):2833–2839.
   PubMed Web of Science ®Google Scholar
• CAMARDA G, BINASCHI M, MAGGI CA, GOSO C: Nuclear factor-KB, induced in human carcinoma cell line A2780 by the new anthracycline MEN 10755, is devoid of transcriptional activity. Int J. Cancer (2002) 102(5):476–482.
   Google Scholar
• CIRILLO R, SACCO G, VENTURELLA S, BRIGHTWELL J, GIACHETTI A, MANZINI S: Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J. Cardiovasc. Pharmacol (2000) 35(1):100–108.
   PubMed Web of Science ®Google Scholar
• ZUCCHI R, YU G, GHELARDONI S, RONCA F, RONCA-TESTONI S: Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2-t) handling and contractile function in rat heart. BE J. Pharmacol (2000) 131(2):342–348.
   PubMed Web of Science ®Google Scholar
• MINOTTI G, PARLANI M, SALVATORELLI Eet al: Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue. BE J. Pharmacol (2001) 134(6):1271–1278.
   PubMed Web of Science ®Google Scholar
• SCHRIJVERS D, BOS A, DYCK Jet al: Phase I study of MEN-10755, anew anthracycline in patients with solid tumours: a report from the EORTC Early Clinical Studies Group. Ann. Oncol (2002) 13(3):385–391.
   PubMed Web of Science ®Google Scholar
• DICKGREBER NJ, WELTE T, GILLISSEN A et al.: Phase II open-label study of MEN-10755 in patients with small cell lung cancer extensive disease (SCLC-ED). Proc. Am. Soc. Clin. Oncol (2003) 22:703 (Abstract 2829).
   Web of Science ®Google Scholar
• CAPONIGRO F, WILLEMSEP, SORIO R et al: A Phase II study of MEN-10755 in patients with advanced or metastatic ovarian cancer. 14th EORTC-NCIAACR Symposium of Molecular Targets and Cancer Therapeutics, Frankfurt, Germany (2002) (Abstract 42).
   Google Scholar
• KRAPCHO AP, PETRY ME, GETAHUN Z et al.: 6,9- bis [(aminoalkyl) amino] benzo isoquinolin e-5,10-diones. A novel class of chromophore modified antitumour anthracene-9,10-diones; synthesis and antitumour evaluations. J. Med. Chem. (1994) 37(6):828–837.
   PubMed Web of Science ®Google Scholar
• BEGGIOLIN G, CRIPPA L, MENTA E et al.: BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori (2001) 87(6):407–416.
   PubMed Web of Science ®Google Scholar
• •Compound selection based on in vivo activity and low cardiotoxicity.
   Google Scholar
• ANDOH T, ISHIDA R: Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta Gene Struct. Expr. (1998) 1400(1-3):155–171.
   PubMed Web of Science ®Google Scholar
• DE ISABELLA P, PALUMBO M, SISSI C et al.: Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol. Pharmacol (1995) 48(1):30–38.
   PubMed Web of Science ®Google Scholar
• ZWELLING LA, MAYES J, ALTSCHULER E, SATITPUNWAYCHA P, TRITTON TR, HACKER MP: Activity of two novel anthracene-9, 10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem. Pharmacol (1993) 46(2):265–271.
   PubMed Web of Science ®Google Scholar
• CAVALLETTI E, CRIPPA L, MELLONI E, BELLINI O, TOGNELLA S, GIULINI FC: BBR 2778, a novel aza-anthracenedione: preclinical toxicological evaluation. Proc. Am. Assoc. Cancer Res. (1993) 34:374 (Abstract 2227).
   Google Scholar
• BERNAREGGI A, TORTI L, RATTI E et al.: Clinical pharmacokinetics of BBR-2778 in patients with malignant lymphoma. Proc. Am. Soc. Clin. Oncol. (1999) 18 (Abstract 730).
   Google Scholar
• DAWSON LK, JODRELL DI, BOWMAN Aet al: A clinical Phase land pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur. Cancer (2000) 36(18):2353–2359.
   PubMed Web of Science ®Google Scholar
• FAIVRE S, RAYMOND E, BOIGE V et al.: A Phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin. .1 Cancer Res. (2001) 7(1):43–50.
   Web of Science ®Google Scholar
• BORCHMANN P, SCHNELL R, KNIPPERTZ Ret al: Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol (2001) 12(5):661–667.
   PubMed Web of Science ®Google Scholar
• BORCHMANN P, MORSCHHAUSER F, PARRY A et al.: Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica (2003) 88(8):888–894.
   PubMed Web of Science ®Google Scholar
• •Full report of Phase II clinical trial.
   Google Scholar
• RALEIGH SM, WANOGHO E, BURKE MD, MCKEOWN SR, PATTERSON LH: Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug. Radiat. Oncol Biol. Phys. (1998) 42(0763–767.
   PubMed Web of Science ®Google Scholar
• WILSON WR, DENNY WA, PULLEN SM et al: Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. Br. J. Cancer (1996) 74\(Suppl. 27):43–47.
   Google Scholar
• SMITH PJ, BLUNT NJ, DESNOYERS R, GILES Y, PATTERSON LH: DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides. Cancer Chemother. Pharmacol. (1997) 39(5):455–461.
   PubMed Web of Science ®Google Scholar
• HEJMADI MV, MCKEOWN SR, FRIERY OP, MCINTYRE IA, PATTERSON LH, HIRST DG: DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells. Br. Cancer (1996) 73(4):499–505.
   Web of Science ®Google Scholar
• FRIERY OP, GALLAGHER R, MURRAY MM et al.: Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine. BL J. Cancer (2000) 82(8):1469–1473.
   Web of Science ®Google Scholar
• PATTERSON LH, MCKEOWN SR, RUPARELIA K et al.: Enhancement of chemotherapy and radiotherapy of murine tumors by AQ4N, a bioreductively activated anti-tumor agent. BE J. Cancer (2000) 82(12):1984–1990.
   Web of Science ®Google Scholar
• •Combination studies of AQ4N and radio-or chemotherapy in vivo.
   Google Scholar
• LOADMAN PM, SWAINE DJ, BIBBY MC, WELHAM KJ, PATTERSON LH: A preclinical pharmacokinetic study of the bioreductive drug AQ4N. Drug Metab. Dispas. (2001) 29(4):422–426.
   PubMed Web of Science ®Google Scholar
• JASZTOLD-HOWORKO R, LANDRAS C, PIERRE A et al: Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5, 6-dimethy06H-pyrido [4,3-b] carbazole-1-N- Rdialkylamino)-alkyllcarboxamides, a new promising series of antitumor olivacine derivatives../. Med. Chem. (1994) 37(15):2445–2452.
   Web of Science ®Google Scholar
• LE MEES PA, MARKOVITS J, ATASSI G, JACQUEMIN-SABLON A, SAUCIER JM: S16020-2, anew highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol. Pharmacol (1998) 53(2):213–220.
   PubMed Web of Science ®Google Scholar
• PIERRE A, LEONCE S, PEREZ V, ATASSI G: Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: Kinetics of uptake and efflux in sensitive and resistant cell lines. Cancer Chemother. Pharmacol (1998) 42(6):454–460.
   PubMed Web of Science ®Google Scholar
• •Studies of the mechanism of resistance to MDR by S-16020–2.
   Google Scholar
• GUILBAUD N, KRAUS-BERTHIER L, SAINT DIZIER D: LI vivo antitumor activity of S16020-2, a new olivacine derivative. Cancer Chemother. Pharmacol (1996) 38(6):513–521.
   PubMed Web of Science ®Google Scholar
• LE ME, S, CHAMINADE F, DELAPORTE C et al: Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N- [2 (dimethylamino)ethyl[carbamoyl side chain. Mol. Pharmacol (2000) 58(4):709–718.
   PubMed Web of Science ®Google Scholar
• GUILBAUD N, JAN M, SAINT DIZIER D et al.: Experimental antitumour activity of S 16020–2 in a panel of human tumours. Eur. .1 Cancer (1997) 33(10:1881–1887.
   Google Scholar
• •Extensive study of the in vivo activity of S16020-2 in human tumour xenografts.
   Google Scholar
• GUILBAUD N, KRAUS-BERTHIER L, SAINT-DIZIER D et al.: Antitumor activity of S 16020-2 in two orthotopic models of lung cancer. Anticancer Drugs (1997) 8(3):276–282.
   PubMed Web of Science ®Google Scholar
• BRILLANCEAU MH, LUCAS C, BRIGGS M, GORDON B, GENISSEL P: Pharmacokinetics and metabolism of the olivacine S-16020 in cancer patients. Proc. Am. Assoc. Cancer Res. (1998) 39:327 (Abstract 2229).
   Google Scholar
• DIPALMA M, BRAIN EC, ETOUSSAMI A et al.: Phase I study of olivacine (S16020) in a weekly schedule: Preliminary results. Proc. Am. Assoc. Cancer Res. (1999) 40:83 (Abstract 555).
   Google Scholar
• AWADA A, BLEIBERG H, GILT et al: Phase I study of S16020, a topoisomerase II inhibitor given q 3 w as a 3-h infusion. Proc. Am. Assoc. Cancer Res. (1999) 40:83 (Abstract 4501).
   Google Scholar
• BRANA ME CASTELLANO JM, MORAN M et al.: Bis-naphthalimides 3: synthesis and antitumor activity of N,IT-bis [2- (1, 8 -naphthalimido) -ethyl] alkanediamines. AntiCancer Drug Des. (1996) 11(4):297–309.
   PubMedGoogle Scholar
• SPICER JA, GAMAGE SA. ATWELL GJ, FINLAY GJ, BAGULEY BC, DENNY WA: Dimeric analogues of non-cationic tricyclic carboxamides are a new class of cytotoxic agents. Anticancer Drug Des. (1999) 14(3):281–289.
   PubMedGoogle Scholar
• BRANA ME RAMOS A: Naphthalimides as anti-cancer agents: synthesis and biological activity. Curr. Med. Chem. Anticancer Agents (2001) 1(3):237–255.
   PubMedGoogle Scholar
• •Broad study of the cytotoxic activity of naphthalimides, leading to selection of elinafide.
   Google Scholar
• BRANA M, WARING MJ, BAILLY C: Sequence-selective intercalation of antitumour bis-naphthalimides into DNA. Evidence for an approach via the major groove. Eur. Biochem. (1996) 240(1):195–208
   PubMedGoogle Scholar
• GALLEGO J, REID BR: Solution structure and dynamics of a complex between DNA and the antitumor bisnaphthalimide LU-79553: intercalated ring flipping on the millisecond time scale. Biochemistry (1999) 38(46):15104–15115.
   PubMed Web of Science ®Google Scholar
• BOUSQUET PF, BRANA ME CONLON D et al: Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity. Cancer Res. (1995) 55(5):1176–1180.
   PubMed Web of Science ®Google Scholar
• VILLALONA-CALERO MA, EDER JP, TOPPMEYER DL et al.: Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies. J. Clin. Oncol (2001) 19(3):857–869.
   PubMed Web of Science ®Google Scholar
• AWADA A, THOEDTMANN R, PICCART Met al: An EORTC-ECSG Phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumors. Eur. J. Cancer (2003) 39(6):742–747.
   PubMed Web of Science ®Google Scholar
• •Full Phase I clinical trial report on elinafide.
   Google Scholar
• MIMURA T, KATO N, SUGAYA Tet al: An efficient synthesis of a new class of DNA intercalating antitumor 7,10-dihydroxy-6H-pyrazolo [4,5,1-del acridin-6-ones. Synthesis (1999) 6:947–952.
   Google Scholar
• SAWYER M, RATAIN MJ, BERTUCCI DM, SCHILSKY RL, KUWABARA T, KINDLER HL: Pharmacokinetics and pharmacodynamics of KW 2170. Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 475).
   Google Scholar
• SAIJO N, NAKAMURA T, MIZUKAMI T et al.: Effect of a novel pyrazoloacridone, KW-2170 on gene expression in various resistance cells determined by cDNA array. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 4587).
   Google Scholar
• ASHIZAWA T, SHIMIZU M, GOMI K, OKABE M: Antitumor activity of KW-2170, a novel pyrazoloacridone derivative. Anticancer Drugs (1998) 9(3):263–271.
   PubMed Web of Science ®Google Scholar
• •Comparison of KW-2170 and doxorubicin in a wide range of human tumour xenografts.
   Google Scholar
• KURAMITSU T, TAKAI K, OHASHI R, KUWABARA T: Determination of the anticancer drug KW-2170, a pyrazoloacridone derivative, and its metabolites in human and dog plasma by high-performance liquid chromatography using an electrochemical detector. Chromatog. B(2002) 768(2):231–237.
   PubMed Web of Science ®Google Scholar
• SAWYER MB, RATAIN MJ, BERTUCCI DM, KINDLER HL, SCHILSKY RL, KUWABARA T: Phase I studies of KW 2170 on two different schedules. Proc. Am. Soc. Clin. Oncol (2001) 20 (Abstract 378).
   Google Scholar
• SAEKI T, EGUCHI K, TAKASHIMA Set al: Phase I study of KW-2170, a novel pyrazoloacridone compound against solid tumors. Proc. Am. Soc. Clin. Oncol (2001) 20 (Abstract 2104).
   Google Scholar
• VERSCHRAEGEN CF: KW-2170 (Kyowa Hakko Kogyo). 'Drugs (2002) 5(10):1000–1003.
   PubMedGoogle Scholar
• YOSHIDA M, KOBUNAI T, AOYAGI K et al.: Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipids. Clin. Cancer Res. (2000) 6(11):4396–4401.
   PubMed Web of Science ®Google Scholar
• ••Interesting paper showing TOP-53Interaction with phosphatidylserine, and suggestions that this results in selective distribution.
   Google Scholar
• BYL J, CLINE SD, UTSUGI T, KOBANAI T, YAMADA Y, OSHEROFF N: DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for the drug action. Biochemistry (2001) 40(3):712–718.
   Google Scholar
• •Comparison of topo II-mediated DNA cleavage by TOP-53 and etoposide.
   Google Scholar
• UTSUGI T, SHIBATA J, SUGIMOTO Y: Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res. (1996) 56(12):2809–2814.
   PubMed Web of Science ®Google Scholar
• KOBUNAI T, SAITO H, YOSHIDA M, TOKO T, TAKEDA S, UNEMI N: LI vitro and in vivo antitumor activity against lung cancer of TOP-53, a novel podophyllotoxin derivative. Proc. Am. Assoc. Cancer Res. (1994) 35:362 (Abstract 2154).
   Google Scholar
• NAGAYAMA S, TSUDA M, KITAMURA Ret al: Tissue distribution of new anticancer drug TOP-53 in nude rats bearing human lung cancer. Proc. Am. Assoc. Cancer Res. (1997) 38:218 (Abstract 1466).
   Google Scholar
• OHASHI Y, ISHIZUKA N, SUZUKI T, YAMAGUCHI T, MINAMI H, SASAKI Y: A hybrid design of pharmacokinetically guided dose escalation (PGDE) and continual reassessment method (CRIVI) in a Phase I trial of TOP-53. A new integrated approach using Bayesian concepts. Proc. Am. Assoc. Cancer Res. (1999) 40:82 (Abstract 545).
   Google Scholar
• MINAMI H, SASAKI Y, OHASHI Yet al: Clinical pharmacokinetics and pharmacodynamics of TOP-53 in comparison with dogs and mice. Proc. Am. Assoc. Cancer Res. (1999) 40:92 (Abstract 607).
   Google Scholar
• KANEKO T, WONG H, UTZIG J, SCHURING J, DOYLE T W: Water soluble derivatives of rebeccamycin. Antibiot. (1990) 43(1):125–127.
   Google Scholar
• LONG B H, ROSE W C, VYAS D M et al.: Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Corr. Med. Chem. Anticancer Agents (2002) 2(2):255–266.
   PubMedGoogle Scholar
• •Review of work leading to the selection on XL-119.
   Google Scholar
• WEITMAN S, MOORE R, BARRERA H, CHEUNG NK, IZBICKA E, VON HOFF DD: In vitro antitumor activity of rebeccamycin analog(NSC 655649) against pediatric solid tumors." Pediatr. Hematol Omni (1998) 20(2):136–139.
   Google Scholar
• TOLCHER A W, ECKHARDT S G, KUHN J et al.: Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties. J. Clin. Oncol (2001) 19(11):2937–2947.
   PubMed Web of Science ®Google Scholar
• •Full report of Phase I clinical trial of XL-119.
   Google Scholar
• DOWLATI A, HOPPEL CL, INGALLS ST et al.: Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. J. Clin. Oncol (2001) 19(8):2309–2318.
   PubMed Web of Science ®Google Scholar
• AFSHI D, REMICK S, SUSA Met al: A Phase I clinical and pharmacokinetic study of rebeccamycin analog (NSC-655649) given daily for five consecutive days. Proc. Am. Soc. Clin. Oncol (1999) 18 (Abstract 694).
   Google Scholar
• LANGEVIN A, WEITMAN S, JUHN S, BERNSTEIN M: A trial of rebeccamycin analog NSC-655649 in children with solid tumors: a Pediatric Oncology Group Phase I cooperative agreement study. Proc. Am. Soc. Oncol (1999) 18 (Abstract 764).
   Google Scholar
• HAMMOND LA, KUHN J, OCHOA L et al.: Phase I and pharmacokinetic (PK) trial of sequences of the rebeccamycin analog, NSC-655649, and cisplatin (CDDP). Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 380).
   PubMed Web of Science ®Google Scholar
• DOWLATI A, POSEY J, RAMANATHAN RK et al.: Multicenter Phase II and pharmacokinetic study of rebeccamycin analogue (RA) in advanced biliary cancers. Proc. Am. Soc. Clin. Omni (2003) 22:267 (Abstract 1070).
   Google Scholar
• IBRAHIM D, HUSSAIN M, LORUSSO P, FLAHERTY L: Rebeccamycin analog (BMY-27557-14) in renal cell cancer (RCC): preliminary results of a Phase II trial. Proc. Am. Soc. Clin. Omni (2001) 20 (Abstract 2373).
   Google Scholar
• CORTAS T, NESS A, CHAPMAN R et al.: Randomized Phase II trial of 2 different administration schedules of rebeccamycin analogue (RA) as 2nd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (2003) 22:668 (Abstract 2686).
   Web of Science ®Google Scholar
• KON K, SUGI H, YAMADA N, TASHIRO T, TSURUO T: A novel antitumor agent IST-622; a chartreusin derivative.' Cancer Res. Clin. Omni (1990) 116 (Suppl. Part 1).
   Google Scholar
• KON K, AOYAMA Y, YAMAMOTO Met al: Mechanism of action of IST-622 a novel antitumor antibiotic chartreusin analogue. Proc. Am. Assoc. Cancer Res. (1992) 33:514 (Abstract 3073).
   Google Scholar
• TASHIRO T, KON K, YAMAMOTO M, YAMADA N, TSURUO T, TSUKAGOSHI S: Antitumor effects of IST-622, a novel synthetic derivative of chartreusin, against murine and human tumor lines following oral administration. Cancer Chemother. Pharmacol (1994) 34(4):287–292.
   PubMed Web of Science ®Google Scholar
• ASAI G, YAMAMOTO N, TOI Met al: Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a Phase II study of patients with breast cancer. Cancer Chemother. Pharmacol (2002) 49(6):468–472.
   PubMed Web of Science ®Google Scholar
• •Full report of Phase II clinical trial of IST-622.
   Google Scholar
• FORTUNE JM, VELEA L, GRAVES DE, UTSUGI T, YAMADA Y, OSHEROFF N: DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Biochemistry (1999) 38(47):15580–15586.
   PubMed Web of Science ®Google Scholar
• UTSUGI T, AOYAGI K, ASAO T et al.: Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. lap. J. Cancer Res. (1997) 88(10):992–1002.
   PubMedGoogle Scholar
• BYL JAW, FORTUNE JM, BURDEN DA et al: DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Biochemistry (1999) 38(47):15573–15579.
   Google Scholar
• ••Detailed biochemical study showing thatTAS-103 is a pure topo IIa inhibitor, not a dual topo I/II inhibitor as proposed earlier.
   Google Scholar
• MINDERMAN H, WRZOSEK C, CAO Set al: Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells. Cancer Chemother. Pharmacol (2000) 45(1):78–84.
   PubMed Web of Science ®Google Scholar
• OHYAMA T, LI Y, UTSUGI Tet al: A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells. fpn. J. Cancer Res. (1999) 90(6):691–698.
   PubMedGoogle Scholar
• AOYAGI Y, KOBUNAI T, UTSUGI T, WIERZBA K, YAMADA Y: Establishment and characterization of 6- [[2- (dimethylamino) ethyl] amino] - 3- hydroxy-7H-indeno[2,1-dquinolin- 7-one dihydrochloride (TAS-103)-resistant cell lines. fpn. J. Cancer Res. (2000) 91(5):543–550.
   PubMedGoogle Scholar
• KAWAGUCHI Y, YAMADA Y, TAJIMA K et al.: Optimal dosing method of TAS-103, a novel quinolone derivative inhibiting DNA topoisomerases. Proc. Am. Assoc. Cancer Res. (2001) 42 (Abstract 556).
   Google Scholar
• AZUMA R, SAEKI M, YAMAMOTO Y, HAGIWARA Y, GROWCHOW LB, DONEHOWER RC: Metabolism and urinary excretion of a new quinoline anticancer drug, TAS-103, in humans. Xenobiotica (2002) 32(1):63–72.
   Google Scholar
• DONEHOWER R, ELZA-BROWN K, O'REILLY S, ISRAEL B, GROCHOW L: A Phase I dose escalation, safety, tolerability and pharmacokinetic study of TAS-103 in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol (1998) 34 (Abstract 806).
   Google Scholar
• EWESUEDO RB, IYER L, DAS S et al.: Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.Oncol (2001)19(7):2084–2090.
   Google Scholar
• •Full report of Phase I clinical trial showing QTc prolongation by TAS-103.
   Google Scholar
• BURRIS HA, JONES SF, HAINSWORTH JD et al.: A Phase I study to determine the safety and pharmacokinetics of BMS-247615 administered once every week in patients with refractory solid tumors. Proc. Am. Soc. Clin. Oncol (2000) 19 (Abstract 742).
   Web of Science ®Google Scholar
• HECK MMS, HITTELMAN WN, EARNSHAW WC: Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Li. USA (1988) 85(4):1086–1090.
   PubMed Web of Science ®Google Scholar
• WHITACRE CM, ZBOROWSKA E, GORDON NH, MACKAY W, BERGER NA: Topotecan increases topoisomerase IIa levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res. (1997) 57(8):1425–1428.
   PubMed Web of Science ®Google Scholar
• HUCHET M, DEMARQUAY D, COULOMB Het al: The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann. NY Acad. Sci (2000) 922:303–305.
   PubMed Web of Science ®Google Scholar
• LAVERGNE O, HARNETT J, ROLLAND A et al: BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Bioorg. Med. Chem. Lett. (1999) 9(17):2599–2602.
   PubMed Web of Science ®Google Scholar
• •Details of the topo inhibition and cell line cytotoxicity of BN-80927.
   Google Scholar
• KASPRZYK PG, LAUER J, CARLSON M et al: In vivo antitumor activity of a dual topoisomerase I/II inhibitor BN80927 against human tumor xenografts. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 5201).
   Google Scholar
• LANSIAUX A, BAL C, WATTEZ Net al: DNA macroarrays to identify genes responsive to apoptosis induced by the homocamptothecins BN80915 and BN80927. Proc. Am. Assoc. Cancer Res. (2002) 43:1086 (Abstract 5380).
   Google Scholar
• UESUGI M, SEKIDA T, MATSUKI S, SUGIURA Y: Selective DNA cleavage by elsamicin A and switch function of its amino sugar group. Biochemistry (1991) 30(27):6711–6715.
   PubMed Web of Science ®Google Scholar
• LORICO A, LONG BH: Biochemical characterisation of elsamicin and other coumarin-related antitumour agents as Potent inhibitors of human topoisomerase II. Eur. J. Cancer (1993) 29A(14):1985–1991.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ C, AZORIN F, PORTUGAL J: Influence of elsamicin A on the activity of mammalian topoisomerase I. Biochemistry (1996) 35(34):11177–11182.
   Google Scholar
• GAVER RC, DEEB G, GEORGE AM: Validated HPLC procedures for the analysis of BMY-28090 in human plasma and urine. Cancer Chemother. Pharmacol (1989) 25(3):195–201.
   PubMed Web of Science ®Google Scholar
• SCHURIG JE, BRADNER WT, BASLER GA, ROSE WC: Experimental antitumor activity of BMY-28090, a new antitumor antibiotic. Invest. New Drugs (1989) 7(203):173–178.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, WANDERS J, NIELSEN AL et al: Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. Ann. Oncol (1994) 5(4):375–376.
   PubMed Web of Science ®Google Scholar
• GOSS G, LETENDRE F, STEWART Det al: Phase II study of elsamitrucin in non-small cell lung cancer. Invest. New Drugs (1994) 12(4):315–317.
   PubMed Web of Science ®Google Scholar
• ALLEN SL, SCHACTER LP, LICHTMAN SM et al.: Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/ relapsed non-Hodgkin's lymphoma. Invest. New Drugs (1996) 14(2):213–217.
   PubMed Web of Science ®Google Scholar
• •Full report of Phase II clinical trial of BN-80927.
   Google Scholar
• SEBOLT JS, SCAVONE SV, PINTER CD et al: Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res. (1987) 47(16):4299-4304. zoo. ADJEI AA, CHARRON M, ROWINSKY EK et al.: Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin. Cancer Res. (1998) 4(3):683–691.
   PubMed Web of Science ®Google Scholar
• GREM JL, POLITI PM, BALIS FM, SINHA BK, DAHUT W, ALLEGRA CJ: Cytotoxicity and DNA damage associated with pyrazoloacridine in MCF-7 breast cancer cells. Biochem. Pharmacol (1996) 51(12):1649-1659. zoz. CAPPS DB, DUNBAR J, KESTEN SR et al.: 2-(Aminoalky6-5-nitropyrazolo13,4,5-4 acridines, a new class of anticancer agents. Med. Chem. (1992) 35(26):4770–4778.
   Google Scholar
• CAPPS DB, DUNBAR J, KESTEN SR et al.: 2-(Aminoalkyl)- 5-nitropyrazolo[3,4,5-kl]acridines, a new class of anticancer agents. J. Med. Chem. (1992) 35(26):4770–4778.
   PubMed Web of Science ®Google Scholar
• PALOMINO E, FOSTER B, KEMPFF M et al.: Identification and antitumor activity of a reduction product in the murine metabolism of pyrazoloacridine (NSC-366140). Cancer Chemother. Pharmacol (1996) 38(5):453–458.
   PubMed Web of Science ®Google Scholar
• FOSTER BJ, WIEGAND RA, LORUSSO PM, BAKER LH: Pharmacokinetics of 9-methoxy-N,N-dimethy1-5-nitropyrazolo [3,4,5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials. Clin. Cancer Res. (1995) 1(8):831–837.
   PubMed Web of Science ®Google Scholar
• BERG SL, BLANEY SM, ADAMSON PC et al: Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. Clin. Oncol (1998) 16(1):181-186. zoo. KUEBLER J, KING GW, TRIOZZI P, MOORE T, KRAUT EH: Phase II study of pyrazoloacridine in metastatic renal cell carcinoma. Invest. New Drugs (2001) 19:327–328.
   Google Scholar
• KUEBLER J, KING GW, TRIOZZI P, MOORE T, KRAUT EH: Phase II study of pyrazoloacridine in metastatic renal cell carcinoma. Invest. New Drugs (2001) 19:327–328.
   PubMed Web of Science ®Google Scholar
• PLAXE SC, BLESSING JA, MORGAN MA, CARLSON J: Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study. Am. Clin. Oncol (2002) 25:45–47.
   PubMed Web of Science ®Google Scholar
• PELLEY R, GANAPATHI R, WOOD L et al.: A Phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer. Cancer Chemother. Pharmacol (2000) 46(3):251–254.
   PubMed Web of Science ®Google Scholar
• ZALUPSKI MM, SHIELDS AF, PHILIP PA et al: Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Invest. New Drugs. (1998) 16(1):93–96.
   PubMed Web of Science ®Google Scholar
• PLAXE SC, BLESSING JA, LUCCI JA, HURTEAU JA: A Phase II trial of pyrazoloacridine (PZA) in squamous carcinoma of the cervix. Invest. New Drugs (2001) 19(1):77–80.
   PubMed Web of Science ®Google Scholar
• PLAXE SC, BLESSING JA, HUSSEINZADEH N, WEBSTER KD, RADER JS, DUNTON CJ: Phase II trial of pyrazoloacridine in patients with persistent or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gyn. Oncol (2002) 84(2):241–244.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, FIPPIN LJ, WHISENANT SP: Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Inv (1998) 16(7):456–461.
   PubMed Web of Science ®Google Scholar
• BASTASCH M, PANELLA TJ, KRETZSCHMER S, GRAHAM D, MAYO M, WILLIAMSON S: Phase II trial of pyrazoloacridine in advanced non-small cell carcinoma of the lung. Invest. New Drugs (2002) 20(3):339–342.
   PubMed Web of Science ®Google Scholar
• BERG SL, BLANEY SM, SULLIVAN J, BERNSTEIN M, DUBOWY R, HARRIS M: Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group Phase II study. J. Pediam Haematol Oncol (2000) 22(6):506–509.
   PubMed Web of Science ®Google Scholar
• KESHELAVA N, TSAO-WEI D, REYNOLDS CP: Pyrazoloacridine is active in multidrug-resistant neuroblastoma cell lines with nonfunctional p53. Clin. Cancer Res. (2003) 9(9):3492–3502.
   PubMed Web of Science ®Google Scholar
• ••Cell line study suggesting a new role forpyrazoloacridine in brain tumours.
   Google Scholar
• LESSER GJ, CARSON K, PRIET R, NABORS LB, DOYLE T, GROSSMAN SA: A Phase I/II trial of pyrazoloacridine (PZA) in adults with newly diagnosed glioblastoma multiforme (GBM). Proc. Am. Soc. Clin. Oncol (2002) 21 (Abstract 2097).
   PubMed Web of Science ®Google Scholar
• ADJEI A, REID J, ERLICHMAN Cet al: A Phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer. Invest. New Drugs (2002) 0(3):297–304.
   Web of Science ®Google Scholar
• CLAIRE DE, ROWINSKY EK, NOE DA et al: A Phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer. Invest. New Drugs (2003) 21(1):75–84.
   PubMed Web of Science ®Google Scholar
• BARRET JM, MONTAUDON D, ETIEVANT Cet al: Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II. Anticancer Res. (2000) 20(6B):4557–4562.
   PubMed Web of Science ®Google Scholar
• PERRIN D, VAN HILLE B, BARRET JM et al: F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem. Pharmacol (2000) 59(7):807–819.
   PubMed Web of Science ®Google Scholar
• BARRET JM, LIMOUZY A, LACASTAIGNERATTE L, HILL BT: Characterization using the TARDIS assay of the effects of F 11782 on cleavable complex formation in V79 cultured cells. Proc. Am. Assoc. Cancer Res. (2002) 43:249 (Abstract 1237).
   Google Scholar
• WALKER JV, NITISS KC, BARRET JM, HILL BT, NITISS JL: The epipodophyllotoxin derivative F 11782 causes an novel mode of inhibition of topoisomerase II. Proc. Am. Assoc. Cancer Res. (2002) 43:250 (Abstract 1249).
   Google Scholar
• BARRETT J M, MENON Y, CREANCIER L, LACASTAIGNERATTE L, HILL BT: Identification of homology with topoisomerases and XPG which might explain the interactions of F 11782 on these proteins. Proc. Am. Assoc. Cancer Res. (2003) 44:406 (Abstract 1788).
   Google Scholar
• BARRET JM, ETIEVANT C, BAUDOUIN C, SKOV K, CHARVERON M, HILL BF: F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-Kl cells. Anticancer Res. (2002) 22(14187–192.
   Google Scholar
• •Report of atypical DNA breakage activity of tafluposide.
   Google Scholar
• BARRET JM, HILL BT, OLIVE PL: Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases. BE J. Cancer (2000) 83(12):1740–1746.
   Web of Science ®Google Scholar
• KRUCZYNSKI A, ETIEVANT C, PERRIN D, IMBERT T, COLPAERT F, HILL BT: Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases. Br. J. Cancer (2000) 83(10:1516–1524.
   PubMed Web of Science ®Google Scholar
• BARRET JM, KRUCZYNSKI A, ETIEVANT C, HILL BT: Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother. Pharmacol (2002) 49(6):479–486.
   PubMed Web of Science ®Google Scholar
• •Extensive cell culture studies showing synergy of talfluposide with other cytotoxics.
   Google Scholar
• SARGENT JM, ELGIE AW, WILLIAMSON CJ, HILL BT: Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs (2003) 16(6):467–473.
   Web of Science ®Google Scholar
• VICKER N, BURGESS L, CHUCKOWREE IS et al.: Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents. J. Med. Chem. (2002) 45(3):721–739.
   PubMed Web of Science ®Google Scholar
• GAMAGE SA, SPICER JA, MILTON Jet al: Structure-activity relationships for pyrido-, imidazo-, pyrazolo-, pyrazino- and pyrrolophenazinecarboxamides as topoisomerase-targeted anticancer agents. J. Med. Chem. (2002) 45(3):740–743.
   PubMed Web of Science ®Google Scholar
• WANG S, MILLER W, MILTON J, VICKER Net al: Structure-activity relationships for analogues of the phenazine-based dual topoisomerase inhibitor XR11576. Bioorg. Med. Chem. Lett. (2002) 12:415–418.
   PubMed Web of Science ®Google Scholar
• MISTRY P, STEWART AJ, DANGERFIELD W et al.: In vitro and in vivo characterisation of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs, (2002) 13(1):15–28.
   PubMed Web of Science ®Google Scholar
• •Detailed mechanism of action studies on XR-11576.
   Google Scholar
• JOBSON A, WILLMORE E, TILBY M, MISTRY P, CHARLTON P, AUSTIN C: Characterisation of the roles of Topoisomerase I and II in the mechanism of action of the novel anti-tumour agent XR11576 (MLN576). Proc. Am. Assoc. Cancer Res. (2003) 44:363 (Abstract 1601).
   Google Scholar
• MCRIPLEY RJ, BURNS-HORWITZ PE, CZERNIAK PM et al.: Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity. Cancer Res. (1994) 54(1):159–164.
   PubMed Web of Science ®Google Scholar
• THOMPSON J, PRATT CB, STEWART CF et al.: A Phase I study of DMP 840 in pediatric patients with refractory solid tumors. Invest. New Drugs (1998) 16(1):45–49.
   PubMed Web of Science ®Google Scholar
• GAMAGE SA, SPICER JA, FINLAY GJ et al.: Dicationic bis(9-methylphenazine-1-carboxamides): relationships between biological activity and linker chain structure for a series of potent topoisomerase-targeted anticancer drugs. J. Med. Chem. (2001) 44(9):1407–1415.
   PubMed Web of Science ®Google Scholar
• •SAR studies leading to the selection of MLN-944.
   Google Scholar
• SPICER JA, GAMAGE SA, REWCASTLE GW et al: bis(phenazine-1-carboxamides): structure-activity relationships for a new class of dual topoisomerase I/II-directed anticancer drugs. J. Med. Chem. (2000) 43(7):1350–1358.
   PubMed Web of Science ®Google Scholar
• STEWART AJ, MISTRY P, DANGERFIELD W et al.: Antitumor activity of XR5944, a novel and potent topoisomerase poison. Anticancer Drugs (2001) 12:359–367.
   PubMed Web of Science ®Google Scholar
• •Demonstration of topo I- and II-induced DNA breakage by MLN-944.
   Google Scholar
• LEWIS LJ, CHARLTON PA, MISTRY P, THOMAS H, COLEY HM: Cellular characterisation and differentiation of XR5944 (MLN944) from XR11576 (MLN576), two novel DNA targeting agents. Proc. Am. Assoc. Cancer Res. (2003) 44:406 (Abstract 1787).
   Google Scholar
• SAPPAL DS, MISTRY P, RUDOLPH OWEN LA: MLN944 (XR5944) regulates cell cycle progression by a novel mechanism compared to known topoisomerase inhibitors. Proc. Am. Assoc. Cancer Res. (2003) 44:634 (Abstract 2780).
   Google Scholar
• FLEMMING JA, BLACKMAN RK, THORODDSEN V, RUDOLPH-OWEN R, CHARLTON P, BULAWA C: Using yeast to probe the mechanism of action of MLN944 (XR5944), a novel bis-phenazine with potent anti-tumor activity. Proc. Am. Assoc. Cancer Res. (2003) 44:1506 (Abstract 6574).
   Google Scholar
• FREATHY C, DANGERFIELD W, SAPPAL DS et al: Comparison of the cellular exposure time of XR5944 (MLN944) and known topoisomerase inhibitors required to induce cell cycle arrest, apoptosis and ultimate cell death. Proc. Am. Assoc. Cancer Res. (2003) 44:835 (Abstract 3652).
   Google Scholar